Comparison of Artecoll, Restylane and silicone for augmentation rhinoplasty in 378 Chinese patients Abstract Purpose: Dermal llers have been proven to be safe in so tissue augmentation; however, their e cacy in modeling the noses of Asian patients has not been demonstrated.
East-Asian noses di er anatomically from Caucasian noses. Typically, the East-Asian nose is characterized by a wide low dorsum, poor nasal tip projection and cartilaginous support and retracted columella [1, 2] . Detailed anatomical studies have also revealed thick lobular skin with abundant subcutaneous fatty tissue, small osteo-cartilaginous framework and weak and thin lower lateral cartilages in the East-Asian nose [3, 4] . Asian patients seeking cosmetic improvement of their noses o en demand a higher and narrower nasal dorsum, a more projected and well-de ned tip and a narrower alar base.
Since 1920s, physicians have attempted to use a wide range of materials, including vaseline, aluminum, ceramics, gold, silver, platinum, celluloid and ivory, for augmentation rhinoplasty. Some materials have been widely used over di erent time periods -and the exploration of the use of these materials has continued for almost 100 years [5] [6] [7] [8] . Because of excessive tissue stimulation, high extrusion rates and brittleness, each of these materials was eventually abandoned. In 1940s, silicone uid injections were used clinically and, a er continuous improvement, a solid implant form was developed and is still widely used in plastic surgery for augmentation rhinoplasty and genioplasty and as silicone rubber shells in breast implants [7] [8] [9] [10] .
In addition to silicone, a variety of biomaterials has been developed and these materials are currently in use for rhinoplasty. Since its introduction into clinical practice in the 1970s, hydroxyapatite has been widely adopted clinically due to the resemblance of its inorganic component to human bone tissue as well as its excellent biocompatibility [11] . Allogeneic tissue augmentation, using bone and/or cartilage from fresh cadavers, is an alternative implant material for rhinoplasty. A er surgery, the allogeneic bone and cartilage acts as a temporary mechanical support but is eventually replaced by autologous bone [6] . Specially treated heterologous tissues, such as bovine nasal cartilage, bovine costal cartilages and calf sternum, have also been used in human rhinoplasty [9] . Autogenous bone is one of the augmentation materials that has been used in rhinoplasty from the very beginning; it is rarely used in primary cosmetic nose surgery today although it is still recommended for complicated nasal deformities or severe saddle nose correction. Costal cartilage is the most commonly used cartilage gra , followed by auricular cartilage and nasal septum cartilage [8] .
An alternative and non-surgical technique for nasal augmentation is the use of injectable tissue llers; i.e., subcutaneous injections to enhance and beautify the nasal shape. Safety should always be considered rst, so any ller material should be non-toxic, non-immunogenic and tissue-biocompatible. Filler substances can be divided into three categories: 1) temporary llers that will be absorbed within 4-6 months (such as collagen and hyaluronic acid) [8] , 2) semi-permanent llers (such as hydroxyapatite and polylactic acid microspheres) that will be absorbed within 9-12 months [11] , and 3) permanent llers (such as uid silicone, polyacrylamide and poly(methyl methacrylate)-microspheres) that are non-absorbable and will remain in the tissues permanently [10] . eoretically, a permanent ller should be preferred for augmentation rhinoplasty, as it does not require ongoing re-treatments but provides a new and improved nasal shape without change in appearance over time. Nevertheless, autologous fat transplantation, collagen injections and hyaluronic acid injections have become the three leading techniques in the cosmetic lling [12] [13] [14] and they have their own bene ts and shortcomings.
In 1996, Artecoll ('CE-mark') was approved by the European Union, and introduced to China in 2002. By the end of 2011, a total of 71,508 ml of Artecoll had been used in 38,456 Chinese patients who received treatment to improve wrinkles, skin depressions, and facial contour de ciencies [15] . With the increased awareness of Artecoll's action and re nements in physicians' injection skills [13] , its applications have expanded gradually from simple deep dermal wrinkle correction to broader indications such as facial feature shaping and structure contour modeling. In order to objectively evaluate the e cacy of Artecoll on the shape and contour modeling through augmentation rhinoplasty, 378 patients recruited through the Department of Plastic Surgery were included in a study that ran between 2003 and 2011. Rhinoplasties were performed using Artecoll or hyaluronic acid (Restylane) injections or solid silicone implantation (Artecoll, n=126; Restylane, n=126 and solid silicone implant, n=126).
Materials and Methods

General data
A total of 1918 Chinese patients with a simple congenital saddle nose and a wide and low dorsum, poor nasal tip projection and poor cartilaginous support received either solid silicone implant surgery or Restylane or Artecoll injections between January 2003 and December 2011. Of the1074 patients who were operated on by insertion of silicone implants, 126 of them provided informed consent for inclusion in this study and had adequate clinical data available. e rst 126 cases from the 563 patients injected with Artecoll and the rst 126 cases from the 281 patients injected with Restylane who provided informed consent and for whom adequate clinical data were available were also included in the study. Each patient was in-formed about the risks and bene ts of all procedures. Each patient paid for the products and the fee for medical care.
e e cacy of nasal dorsum augmentation and tip contour modeling was evaluated. Prior to surgery or injection, the history of allergies, endocrinologic, hematologic and immune diseases was recorded. If patients developed common acute diseases, no surgery was performed until they recovered completely. is study was approved by the Research Ethics Board of our hospital.
Medical records of these patients were reviewed to collect surgery and anesthesia-related information, details on preoperative and postoperative care, and treatments out of hospital.
e patient characteristics included age, gender, etiology, surgical site, operational procedures, dose of llers, possible complications and surgical repair methods for complications (when necessary).
e subjective and objective outcomes of augmentation rhinoplasty were evaluated on day 1 and at 1, 3, 6 and 12 months a er surgery and photos were taken at all visits
Injection of Artecoll and Restylane
Artecoll was obtained from Hafod B.V. (Rotterdam, e Netherlands) and Restylane was obtained from Q-Med AB (Uppsala, Sweden). Note that Artesense and Artecoll are different names for the same product. A er the fourth generation production, Artecoll was changed to Artesense worldwide, with the exception of mainland China. Topical anesthesia cream was applied to the patients 30-60 minutes before injection. A 27-G needle (0.5 mm) was used to determine the thickness of the dermis. e "tunneling technique" [16] was employed to deliver the implant between periost and subdermis while withdrawing the needle slowly during injection. Slow and continuous withdrawal under constant injection pressure is crucial to achieve even ller placement and to avoid the occurrence of irregularities and nodules. Scratching the needle tip on the periosteum under pressure may assure the product delivery in the right subcutaneous plane (Figure 1a) . If the needle hits the dermal layers and the skin turns pale, the injection should be stopped immediately and the material in the pale part must be spread out evenly. A er each injection, any potential small, palpable irregularities should be modeled in place ( Figure 1b ). An external xation with a thermoplastic splint for 24 hours was used to help shape the entire nose (both nasal dorsum and nasal tip) ( Figure 1c ).
Insertion of Silicone Implants
Under local anesthesia with 2% lidocaine, an incision of about 1 cm was made on the upper wall of the right nasal columella. Separating the skin from the periosteum up to 0.5 cm below the line connecting the two eyebrows creates a tight pocket for silicone implant insertion. A custom-made silicone implant, obtained from Winner Corporation (Shanghai, China) was chosen and trimmed according to the defect of the nose and the desire of the patient. A er insertion of the implant, the columellar incision was sutured. An external xation with a thermoplastic splint for 24 hours was used to help shape the entire nose (both nasal dorsum and nasal tip).
Clinical Assessment e e cacy of injections or surgery was evaluated according to the assessment of the cosmetic improvement of the nasal augmentation and the degree of satisfaction by the patients and doctors, using comprehensive assessment scores.
Adverse Events a er Augmentation Rhinoplasty
Adverse events (AEs) were categorized into acute and delayed e ects. Acute AEs were usually mild and of short duration, mostly self-limiting and included erythema, ecchymosis, pain, itching, bleeding, swelling and infection. In most cases, no treatment, or only symptomatic treatment, was required. Delayed AEs are usually severe and rare and included allergic reactions, hypertrophic scars, thrombosis, in ammation and granulomatous reaction. All delayed AEs require further treatment. Permanent llers are more prone to causing foreign body reactions such as granulomas.
Pathological Examination
At 12 months a er surgery, a 2×3×3 mm 3 specimen was collected from patients who experienced delayed AEs. Tissue samples were embedded in para n and processed for H.E staining and subsequent histological examinantion.
Statistical Analysis
AEs were described as total counts of events and subjects experiencing adverse events. e number of treatments and the quantity of product were compared by using an independent ttest. Non-parametric tests were used for comparisons of rates. Mann-Whitney U-test was employed to compare the surgical improvements and patient and doctor satisfaction on the basis of observer-rated and investigator-rated "Rhinoplasty Assessment Scale" scores among groups. Rater reliability for observer "Rhinoplasty Assessment Scale" ratings was analyzed using intra-class correlation. A value of p<0.05 was considered statistically signi cant.
Results
A total of 378 patients received augmentation rhinoplasty and had complete clinical information. No patient was lost to follow-up. ere were no signi cant di erences with regard to the gender, age, and outcome expectations among the three groups (Artecoll, Restylane and silicone). All patients received augmentation and shaping of the entire nose (the nasal dorsum and the nasal tip). e dose of Artecoll used was signi cantly lower than that of Restylane (p <0.01), but the same e ect was achieved (Table 1) .
Adverse Events
Patients receiving silicone implants experienced signi cantly more nasal and upper facial traumatic reactions, skin swelling or intense pain (requiring oral pain medication) during the rst week a er surgery. Nasal hematomas occurred in 32 patients of the silicone implant group but resolved within two weeks. Silicone implants had to be removed in six patients due to infection and silicone implant exposure was found in another four cases. Conspicuous red angiogenesis was observed in 10 patients: six patients had nasal deviation, two showed hyperplastic capsule formation and two developed nasal tissue granulomas. Symptomatic treatment and re-operations were performed due to these complications.
In the Restylane and Artecoll groups, acute AEs, including mild swelling, pain and redness, occurred at all injection sites and lasted for 1-3 days. In the Restylane group, two patients experienced mild hyperpigmentation at the injection site but this resolved spontaneously within 6 months and three patients developed mild subcutaneous nodules, which disappeared within half an hour a er hyaluronidase injection. One patient developed infection, two had hematoma and one presented with nasal deviation. Within one year a er injection, Restylane was completely absorbed in 89 patients (70.6%) and the patients' noses returned to pre-treatment shape.
In the Artecoll group, the number of AEs was signi cantly lower: only one patient had subcutaneous bleeding, which resolved within one week, one patient developed a 0.5 mm 3 subcutaneous nodule, which disappeared within two weeks a er one injection of 0.5% triamcinolone. No acute/chronic allergic reactions, in ammatory granulomas, skin infections, abscesses, infarction or other serious complications were found in these patients ( Table 2 ).
E cacy of Augmentation Rhinoplasty
Signi cant improvement was objectively noted in the nasal shape and contour immediately a er surgery or injection in all the patients who stated that they were satis ed with the outcome. As the number of delayed AEs increased, the nasal shape and contour were compromised, and the cosmetic results also reversed. Some patients could not tolerate the AEs, especially those patients treated with silicone implants, and they complained about the signi cant traumatic response, skin swelling, 
Imaging Examination before and a er Injection
During the rst year, ndings in image examination before and a er rhinoplasty were compared among the three groups. Artecoll injection was found to be superior to either Restylane injection or silicone implants with regard to maintaining nasal shape and contour, incidence of AEs and degree of subjective satisfaction (Figures 2 and 3) .
Follow-Up
Silicone implants with a preformed and tailored shape provide a straight contour, which may be prone to shi ing. e solid silicone puts great pressure on the skin of the nose tip, causing swelling and congestion of the skin, with the risk of perforation. In contrast, augmentation with Restylane or Artecoll exerts no pressure on the nasal skin and has the advantage of mold ability during the rst week post-treatment. Small irregularities and defects could be improved by further lling. A er surgery or injection, patients were followed up for one year, the nasal elevation a er Artecoll injection remained nearly consistent, while elevation with Restylane injection was signi cantly compromised (P<0.01) (Figure 4 ). Specimens were collected at 12 months a er surgery, and histological examination showed the Artecoll poly(methyl methacrylate) (PMMA) particles were completely encapsulated with autologous collagen, while Restylane was completely absorbed. Chronic in ammation was found around some silicone implants with thickened capsule ( Figure 5 ).
Discussion
For nearly a century, physicians have investigated the use of di erent solid and injectable materials for use in augmentation rhinoplasty; however, many materials cause pain and other AEs in patients [17] . Liquid para n was used as ller material but was discontinued when it was found that para nomas developed years a er injection [10] . Similarly, in the 1930s, vaseline was injected for so tissue lling of di erent body parts, but was discontinued when tumor-like proliferation occurred 6-8 years a er injection. In 1953, Baronders reviewed the use of liquid silicone for so tissue augmentation and concluded that the chronic in ammation observed a er liquid silicone injection was unacceptable [10, 17] . In 1975, bovine collagen was introduced into clinical practice as wrinkle ller [18] and in 1981, Zyderm® (a bovine collagen product) was approved by the FDA [19] . In 1994, a modi ed sodium hyaluronate gel from Q-Med AB Sweden was approved in the Europe [11] . In 1996, Artecoll (CE-mark) was approved by the European Union (EU) and has been used in the EU and worldwide since then [16] . In 1996, polyacrylamide (PAM) was introduced into clinical practice as Aquamid® [20] . In 2004, Restylane (a haluronic acid ller from Q-Med AB, Sweden) was approved in the USA by the FDA. In October 2006, ArteFill® was approved by the FDA and this new permanent ller was found to possess signi cant advantages over absorbable substances. An ideal ller material for so -tissue augmentation should have the following characteristics: (1) safe, with good biocompatibility; (2) exhibit tissue stability; (3) capable of maintaining a xed volume and exibility; (4) be stable against dissolution and phagocytosis; and (5) show no migration or dislocation [16] . An analysis of all injectable llers used in the past 10 years has revealed that each have their own advantages and disadvantages [13] .
Hyaluronic acid and collagen are stromal components of the skin. ey have hydrophilic properties and can increase the volume and exibility of the dermis [21] . Some of the currently [22] . Restylane may also cause itching and subcutaneous discoloration at the injection site. Soparkar et al. [21] reported that hypersensitivity to bacterial hyaluronic acids occurred in 0.005% to 0.42% of patients. One advantage of this ller is that hyaluronidase can be used to treat early complications. e primary drawback of hyaluronic acid is its complete absorption within 6-12 months; therefore, hyaluronic acid does not meet the requirements of maintaining long-term e cacy in augmentation rhinoplasty. If its degradation time could be prolonged to ve years, Restylane may become the ller of choice. Radiesse (calcium-hydroxyapatite) is a semi-permanent injectable ller with low solubility and a longevity of 9-12 months. Few AEs have been reported and the incidence of immunologic reactions is extremely low. On the other hand, it can cause a high incidence of submucosal nodules in so tissue when spread unevenly [11] . Radiesse appears radiopaque on Xrays and may interfere with facial imaging.
Aquamid is marketed as a permanent ller. Although the polyacrylamide polymer is non-toxic, the acrylamide monomer may be neurotoxic and teratogenic [12] . Furthermore, polyacrylamide hydrogel may migrate and cause in ammation and granulomatous reactions. A reported complication rate was 6.74%, especially when it was used for breast augmentation where it may cause granulomas in the surrounding tissues and hyaline degeneration [12] .
Nasal augmentation with solid silicone implants has been performed for more than 70 years and is still being widely used by plastic surgeons. Its advantages include easy shaping, short operation time and feasibility for all nose shapes [1, 2] ; however, there is a high incidence of complications, such as shi ing and dislocation of the implant and bleeding and infection a er operation. Furthermore, it is prone to cause teleangiectasia over the nasal tip; thus, straight silicone implants are not recommended for tip surgery alone.
Artecoll is a safe and predictable permanent injectable ller and has been used clinically over the past 15 years and in over 500,000 patients world-wide [23] . Artecoll has been found to work quite well in correcting facial wrinkles (such as forehead lines, frown lines, shtail lines, lower lid shadows, nasolabial folds, ne perioral wrinkles and cervical folds), acne scars and traumatic depressions in ear lobes, nasal bridge and columella, alar depressions, sunken cheeks, small lips and receding chins [23] . Artecoll is composed of 20% v/v PMMA microspheres (with a diameter of 32-40 microns) suspended in a solution of 80% v/v bovine collagen (from BSE-free herds in Australia) and 0.3% lidocaine. Once the smooth PMMA microspheres enter the subdermal so tissues, they are covered by brin and later by macrophages and broblasts, which produces a ne collagen capsule around these millions of microspheres. e capsule not only avoids phagocytosis by macrophages, but minimizes the irritation of so tissues and dislocation [16] . Within 1-3 months, the collagen is gradually degraded and completely replaced by the host tissue, while the PMMA will not be degraded and remains permanently at the injection site [13] .
e 32-40 micron PMMA microspheres in the Artecoll represent the ideal particle size; large enough to avoid phagocytosis [24, 25] and small enough to successfully pass through the 26 G to 31 G diameter needles. Microspheres in this size range also possess other advantages: smaller microspheres have a larger total surface area, which stimulates the generation of more collagen. when the average diameter of microspheres is 40 microns, the new autologous connective tissues ingrowth will reach about 80% by volume but when the diameter of microspheres increases to 100 microns, the new connective tissue is only about 56% by volume [24] . e primary advantage of collagen as a carrier is its ideal viscosity [25] that keeps the PMMA microspheres evenly suspended and also leaves spaces between the well-aligned microspheres to facilitate the ingrowth of the tissues. It is interesting that the e ective results of the Artecoll injection are superior to the surgical procedure.
e former technique uses less material and is easier to mold than the latter. Other biological wrinkle llers, such as Zyplast and Restylane are metabolized and absorbed completely within 6-12 months [26, 27] .
Adverse Events
Artecoll has been used in China for more than 10 years and 38,456 patients have been treated with it. e incidence of severe AEs is less than 0.05% [28] . In the present study, of the 126 Artecoll-treated patients, only one developed a subcutaneous hematoma at the injection site and one showed transient nodules (disappearing a er massage). e incidence of AEs was signi cantly lower than that in both the Restylane and the solid silicone implant groups. Granuloma formation a er Artecoll treatment is a reported complications, but very rare: only four cases of granuloma were reported a er injection of an earlier generation of Artecoll, and two of the pateints with potential granuloma were treated with intralesional corticosteroid (triamcinolone) injections. Surgical resection should be the last option [29] .
Conclusion
Our results showed that all 378 patients had signi cant improvement in nasal shape and contour immediately a er surgery or injection. Our results also con rm that Artecoll is a safe so tissue ller for augmentation rhinoplasty and superior to both Restylane injections and solid silicone implants. With a lower incidence of AEs, Artecoll additional advantages over the other two treatments for augmentation rhinoplasty. Similar results are expected in other patient populations.
